Clinical trials: Docetaxel, completed
Prostatic Neoplasms
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
This is a randomized phase II trial including 40 patients with castration resistant metastatic cancer prostate (CRMPC). Patients will be randomized between treatment with a dendritic cell vaccine plus docetaxel and docetaxel…
- Trial name
- NCT01446731
- Testing
- mRNA transfected dendritic cell, Docetaxel
- Where
- 2 sites in Denmark
- Volunteers
- 43 people
- Sponsor
- Inge Marie Svane
Prostate Cancer
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with…
- Trial name
- NCT07477756
- Where
- United States
- Volunteers
- 1,247 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Squamous Cell of Head and Neck
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
Locally advanced squamous cell carcinoma of the head and neck (SCCHN) is treated with various combinations of radiation and chemotherapy.
- Trial name
- NCT01588431
- Testing
- Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-Squamous Non-Small Cell Lung Cancer
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC.
- Trial name
- NCT01351415
- Testing
- Bevacizumab, Docetaxel, Erlotinib
- Where
- 179 sites in United States, Argentina and 16 more
- Volunteers
- 485 people
- Sponsor
- Hoffmann-La Roche
Metastatic Transitional Cell Cancer of the Urothelial Tract
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
The purpose of this non-randomized Phase II trial was to evaluate the efficacy of a combination of docetaxel and oxaliplatin in patients with metastatic transitional cell cancer (TCC) of the urothelial tract.
- Trial name
- NCT03159143
- Testing
- Docetaxel, Oxaliplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Leonard Appleman
Nasopharyngeal Carcinoma, Malnutrition
The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
The purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma…
- Trial name
- NCT03240835
- Testing
- cisplatin and docetaxel, IMRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhao Chong
Breast Cancer
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Treatment strategies that include induction chemotherapy have several potential advantages: early initiation of systemic chemotherapy, in vivo assessment of response, and down-staging of both the primary tumor and regional…
- Trial name
- NCT00193050
- Testing
- Gemcitabine, Epirubicin, Docetaxel
- Volunteers
- 110 people
- Sponsor
- SCRI Development Innovations, LLC
Non-Small-Cell Lung Cancer
Phase II Trial of Continuation Therapy in Advanced NSCLC
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.
- Trial name
- NCT03083808
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Greg Durm, MD
Head and Neck Cancer
Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer
This phase II trial is evaluating the efficacy of concurrent chemoradiation therapy with weekly docetaxel and cisplatin combination regimen.
- Trial name
- NCT01126008
- Testing
- CCRT with weekly docetaxel & cisplatin
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Samsung Medical Center
Non Small Cell Lung Cancer
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
- Trial name
- NCT00890825
- Testing
- AZD6244, docetaxel
- Where
- 63 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms, Prostate Cancer
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow…
- Trial name
- NCT00485303
- Testing
- Abiraterone acetate, Prednisone
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 58 people
- Sponsor
- Cougar Biotechnology, Inc.
Non-Small Cell Lung Cancer
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens.
- Trial name
- NCT00085826
- Testing
- Exisulind
- Where
- 114 sites in United States
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer
DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
- Trial name
- NCT02838225
- Testing
- Docetaxel, Doxorubicin, Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Non-small Cell Lung Cancer
Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn how effective the combination of the drugs imatinib mesylate (Gleevec®) and docetaxel (Taxotere®) is in treating non-small cell lung cancer (NSCLC).
- Trial name
- NCT01083589
- Testing
- Imatinib Mesylate, Docetaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out if giving Reolysin in combination with docetaxel and prednisone can offer better results than standard therapy with docetaxel and prednisone.
- Trial name
- NCT01619813
- Testing
- Docetaxel, Reolysin and Prednisone, Docetaxel and Prednisone
- Where
- 11 sites in Canada
- Volunteers
- 85 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Gastric Cancer
Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
The purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and bevacizumab are effective in the treatment of unresectable advanced gastric cancer.
- Trial name
- NCT01471470
- Testing
- Docetaxel, Capecitabine, Cisplatin, Bevacizumab
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Asan Medical Center
Prostate Cancer
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as nilutamide, bicalutamide, flutamide, or cyproterone may stop the adrenal glands from producing androgens.
- Trial name
- NCT00055731
- Testing
- bicalutamide, Goserelin Acetate, docetaxel
- Where
- 38 sites in France
- Volunteers
- 413 people
- Sponsor
- UNICANCER
Cancer
A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters…
- Trial name
- QUTIE (NCT00876044)
- Testing
- aflibercept (AVE0005)
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 88 people
- Sponsor
- Sanofi
Metastatic Hormone-sensitive Prostate Cancer
An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care
This is an observational study in which only observations from routine clinical practices will be made. Participants will not receive any advice on treatment or any changes to healthcare as a part of the study.
- Trial name
- BELBEQA (NCT06498921)
- Testing
- Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel
- Where
- Belgium
- Volunteers
- 106 people
- Sponsor
- Bayer
Bladder Cancer, Urothelial Carcinoma
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense oligonucleotide (ASO), in combination with docetaxel…
- Trial name
- NCT01780545
- Testing
- OGX-427, Docetaxel
- Where
- 35 sites in United States
- Volunteers
- 200 people
- Sponsor
- Noah Hahn, M.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.